Peptide questions · Teriparatide
Teriparatide side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for teriparatide are joint pain, pain and nausea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: The current Forteo label has no boxed warning.
What is commonly reported with teriparatide
- Joint pain
- Pain
- Nausea
- Dizziness
- Leg cramps
- Light-headedness on standing (first doses)
- Brief rise in blood calcium
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 18) |
|---|---|
| Joint pain | None: listed for Teriparatide alone |
| Pain | None: listed for Teriparatide alone |
| Nausea | 6: BPC-157, TB-500, AOD-9604, Larazotide and 2 more |
| Dizziness | 2: BPC-157, Abaloparatide |
| Leg cramps | None: listed for Teriparatide alone |
| Light-headedness on standing (first doses) | None: listed for Teriparatide alone |
| Brief rise in blood calcium | None: listed for Teriparatide alone |

Which teriparatide side effects the healing & recovery group shares
Across the 19 healing & recovery compounds in the library, the effects listed most often are headache (7 of 19), injection site reaction (7 of 19), nausea (7 of 19) and fatigue (6 of 19). Teriparatide shares 2 of its 7 listed effects with at least one other healing & recovery compound; joint pain, pain, leg cramps, light-headedness on standing (first doses) and brief rise in blood calcium are listed for teriparatide alone.
What the teriparatide safety notes say
The library’s safety note
The current Forteo label has no boxed warning. Rats given teriparatide for most of their lives developed osteosarcoma, a bone cancer, at every dose; in people, two US surveillance studies found 3 cases among 379,283 users and none among 153,316, a risk similar to comparison groups, and data beyond 2 years are limited. So the label avoids it in anyone with a raised baseline risk: growing bones (children and young adults), Paget's disease or another bone disease, bone cancer or bone metastases, or radiation to the skeleton. It can raise blood calcium, so it is avoided with an existing high-calcium disorder such as primary hyperparathyroidism; rare skin calcification (calciphylaxis) has been reported; kidney stones call for a risk-benefit talk. In 5% of healthy volunteers the first doses brought brief light-headedness on standing, so the first shots are given sitting or lying down. Serious allergic reactions have been reported. These are label findings; review them with your clinician.
The library’s interaction note
Teriparatide raises blood calcium for a few hours after each dose, and high calcium can make digoxin more toxic, so the label suggests watching for digoxin toxicity in people on both. Calcium and vitamin D are added if the diet falls short, and can be taken at the same time (label). Discuss all your medicines with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the teriparatide reports come from
The library rates the evidence on teriparatide as established: clinical trials or FDA-approved use exist.
Of the library’s 7 research notes on teriparatide, 5 rest on randomized trials, 1 on clinical data and 1 on community reports.
Our 10 study pages on teriparatide: 3 meta-analyses, 1 clinical trial and 6 randomized trials.
So teriparatide has controlled trials in people to set its listed effects against.
What our teriparatide study pages report on safety
Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)
Meta-analysis, human, 2024: Neither raised the rate of adverse events: teriparatide RR 0.92 (P = 0.32) and denosumab RR 0.98 (P = 0.37). Across 23 head-to-head trials, teriparatide beat bisphosphonates on fracture risk and bone density in people not previously on a bisphosphonate, without more adverse events.
Teriparatide then denosumab: 21.9% spine bone density gain
Clinical trial, human, 2022: Trabecular bone score, a score of the spongy inner bone's structure, rose 5.8%; blood markers of bone turnover fell 75% to 85% by 3 months and stayed low through 12 months, and denosumab was generally well tolerated.
Teriparatide: 45.4% of jaw osteonecrosis lesions resolved by 52 weeks
Randomized trial, human, 2020: Side effects were about as common in both groups and mostly mild, such as nausea, poor appetite and muscle or bone pain. In a small controlled trial, a short teriparatide course added to standard care helped more MRONJ lesions resolve than placebo, with mostly mild side effects.
Questions people ask
What are the side effects of teriparatide?
The side effects most commonly reported for teriparatide are joint pain, pain and nausea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Do teriparatide’s side effects come from human studies?
The library rates the evidence on teriparatide as established, and the library’s evidence on it includes controlled trials in people.
Which teriparatide side effects are its own?
Among the healing & recovery compounds, the library lists joint pain, pain, leg cramps, light-headedness on standing (first doses) and brief rise in blood calcium for teriparatide alone.
Does teriparatide interact with other medicines?
The library’s interaction note on teriparatide begins: teriparatide raises blood calcium for a few hours after each dose, and high calcium can make digoxin more toxic, so the label suggests watching for digoxin toxicity in people on both.